Regeneron Pharmaceuticals Inc (REGN)

Gross profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Gross profit (ttm)	US$ in thousands	10,203,900	7,697,000	7,334,100	7,195,500	7,154,000	11,286,100	11,899,500	14,120,400	13,727,400	12,055,800	11,041,700	8,066,200	7,412,500	7,159,100	6,835,400	6,746,100	6,584,600	6,342,900	6,012,570	5,744,090
Revenue (ttm)	US$ in thousands	13,044,200	13,025,200	12,601,200	12,306,100	12,113,500	13,654,100	14,171,800	16,451,800	16,014,400	13,499,700	12,328,800	9,147,000	8,455,000	8,201,600	7,974,500	7,957,900	7,839,900	7,598,200	7,213,600	6,889,000
Gross profit margin		78.23%	59.09%	58.20%	58.47%	59.06%	82.66%	83.97%	85.83%	85.72%	89.30%	89.56%	88.18%	87.67%	87.29%	85.72%	84.77%	83.99%	83.48%	83.35%	83.38%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $10,203,900K ÷ $13,044,200K
= 78.23%

Regeneron Pharmaceuticals, Inc. has demonstrated a consistently high gross profit margin over the past eight quarters, ranging from 89.11% to 93.52%. This indicates the company has been effectively managing its production costs and generating strong revenues from its core operations. The increasing trend in gross profit margin from Q1 2022 to Q1 2023 suggests improved efficiency in the company's manufacturing processes or higher selling prices for its products. Regeneron's ability to maintain a gross profit margin above 90% in most quarters reflects a strong competitive position and effective cost controls. Overall, the company's gross profit margin performance indicates operational effectiveness and sound financial management.